Portola Pharmaceuticals Inc. (NASDAQ:PTLA) was up 3.9% during trading on Monday . The stock traded as high as $27.56 and last traded at $26.97, with a volume of 495,337 shares trading hands. The stock had previously closed at $25.96.

Several equities research analysts recently commented on PTLA shares. Morgan Stanley reduced their price target on shares of Portola Pharmaceuticals from $71.00 to $70.00 in a research report on Friday, April 8th. Zacks Investment Research downgraded shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 13th. Credit Suisse Group AG downgraded shares of Portola Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $33.00 to $30.00 in a research report on Tuesday, May 31st. Finally, Citigroup Inc. upped their price objective on shares of Portola Pharmaceuticals from $29.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, May 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $41.07.

The firm’s market cap is $1.52 billion. The company has a 50-day moving average of $24.19 and a 200 day moving average of $26.49.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.06) by $0.09. During the same period last year, the company posted ($0.95) EPS. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $7.91 million. Portola Pharmaceuticals’s revenue for the quarter was up 245.8% compared to the same quarter last year. Equities research analysts forecast that Portola Pharmaceuticals Inc. will post ($5.17) earnings per share for the current year.

Several large investors have modified their holdings of PTLA. State Board of Administration of Florida Retirement System boosted its stake in shares of Portola Pharmaceuticals by 2.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 21,017 shares of the biopharmaceutical company’s stock valued at $1,081,000 after buying an additional 430 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Portola Pharmaceuticals by 3.6% in the fourth quarter. New York State Common Retirement Fund now owns 68,123 shares of the biopharmaceutical company’s stock valued at $3,505,000 after buying an additional 2,376 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Portola Pharmaceuticals by 5.8% in the fourth quarter. Nationwide Fund Advisors now owns 46,890 shares of the biopharmaceutical company’s stock valued at $2,412,000 after buying an additional 2,590 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Portola Pharmaceuticals by 16.7% in the fourth quarter. Rhumbline Advisers now owns 49,370 shares of the biopharmaceutical company’s stock valued at $2,540,000 after buying an additional 7,075 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Portola Pharmaceuticals by 17.2% in the fourth quarter. California Public Employees Retirement System now owns 56,000 shares of the biopharmaceutical company’s stock valued at $2,881,000 after buying an additional 8,200 shares in the last quarter.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.